Organization

The Children's Hospital of Zhejiang University School of Medicine

6 clinical trials

1 abstract

Abstract
Efficacy and safety of FCN-159, a MEK1/2 inhibitor in pediatric participants with neurofibromatosis type 1: Results from a phase 2 trial.
Org: The Children's Hospital of Zhejiang University School of Medicine, NanFang Hospital of Southern Medical University, Shanghai Ninth People's Hospital, Shanghai Fosun Pharmaceutical Industrial Development CO., Ltd.,